US 12,226,475 B2
Treatment of insect bite hypersensitivity
Antonia Fettelschoss, Münchwilen (CH); and Martin Bachmann, Rämismühle (CH)
Assigned to UNIVERSITÄT ZÜRICH, Zürich (CH)
Filed by UNIVERSITÄT ZÜRICH, Zürich (CH)
Filed on May 23, 2022, as Appl. No. 17/750,896.
Application 17/750,896 is a continuation of application No. 16/721,847, filed on Dec. 19, 2019, granted, now 11,382,970.
Application 16/721,847 is a continuation of application No. 15/758,052, granted, now 10,556,003, issued on Feb. 11, 2020, previously published as PCT/EP2016/071078, filed on Sep. 7, 2016.
Claims priority of application No. 15184195 (EP), filed on Sep. 8, 2015; application No. 16166342 (EP), filed on Apr. 21, 2016; and application No. 16175211 (EP), filed on Jun. 20, 2016.
Prior Publication US 2022/0354946 A1, Nov. 10, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 39/35 (2006.01); A61P 17/00 (2006.01); A61P 17/02 (2006.01); A61P 37/08 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01); C07K 14/54 (2006.01)
CPC A61K 39/35 (2013.01) [A61P 17/00 (2018.01); A61P 17/02 (2018.01); A61P 37/08 (2018.01); C12N 7/00 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/552 (2013.01); A61K 2039/58 (2013.01); C07K 14/54 (2013.01); C12N 2770/14023 (2013.01); C12N 2770/14034 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A composition comprising:
(a) a core particle with at least one first attachment site; and
(b) at least one antigen with at least one second attachment site, wherein said at least one antigen is an equine Interleukin-5 antigen (eIL-5 antigen), wherein said eIL-5 antigen comprises a protein with the amino acid sequence selected from SEQ ID NO:1 or a protein with an amino acid sequence of at least 90% amino acid sequence identity with SEQ ID NO:1;
wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond, and wherein said first attachment site is an amino group and said second attachment site is a sulfhydryl group.